(19) (712) 1,797 (1,109)
Gain on extinguishment of
development financing
obligation - - - 31,592
Gain on sale of products 715 - 5,860 -
Net loss (60,020) (20,535) (138,826) (59,391)
Beneficial conversion
feature - (18,419) - (21,920)
Loss attributable to common
stockholders $(60,020) $(38,954) $(138,826) $(81,311)
Loss per share attributable
to common stockholders,
basic and diluted $(2.53) $(2,043.15) $(10.04) $(6,254.69)
Weighted-average common
shares used in computing
loss per share attributable
to common stockholders,
basic and diluted 23,694 19 13,829 13
JAZZ PHARMACEUTICALS, INC.
SUMMARY OF PRODUCT SALES, NET
(In thousands)
(Unaudited)
Three Months Ended Year Ended
December 31, December 31,
2007 2006 2007 2006
Xyrem $11,120 $8,082 $39,018 $29,049
Antizol 3,740 3,472 14,153 12,813
Cystadane (1) - 336 365 1,437
Total $14,860 $11,890 $53,536 $43,299
(1) Jazz Pharmaceuticals, Inc. sold its rights to Cystadane to an
unrelated third party in March 2007.
JAZZ PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands)
'/>"/>
SOURCE Jazz Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1.
Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)2.
Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer3.
Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors4.
Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance5.
Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan6.
NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 20077.
Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting8.
Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors9.
Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference10.
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT11.
Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007